Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

3.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.4K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.4K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

3.2K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
3.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing a Curricular Model for Structured Reflection in a Neurology Clinical Clerkship.

Journal of medical education and curricular development·2025
Same author

[High expression of SURF4 promotes migration, invasion and proliferation of gastric cancer cells by inhibiting tight junction proteins].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2025
Same author

Fibrinogen-albumin-ratio is an independent predictor of deep vein thrombosis in patients undergoing knee arthroplasty.

Journal of orthopaedics·2025
Same author

Protamine-Facilitated Same-Day Discharge Following Distal Transradial Angiography.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Targeted Inhibition of cGAS/STING signaling induced by aberrant R-Loops in the nucleus pulposus to alleviate cellular senescence and intervertebral disc degeneration.

Journal of nanobiotechnology·2025
Same author

Modulating mitochondrial dynamics in CMT2A: a multifaceted platform for drug discovery and evaluation.

Biophysics reports·2025

Related Experiment Video

Updated: Aug 16, 2025

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.7K

The star target in SLE: IL-17.

Yi Yang1, Chen Yan1, Le Yu1

  • 1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|December 20, 2022
PubMed
Summary
This summary is machine-generated.

Interleukin-17 (IL-17) plays a key role in systemic lupus erythematosus (SLE) pathogenesis. Targeting IL-17 shows significant promise for developing novel SLE therapies.

Keywords:
Interleukin-17Lupus nephritisSystemic lupus erythematosusT cellsTreatment targets

More Related Videos

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells
12:38

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells

Published on: December 18, 2008

11.3K
Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

579

Related Experiment Videos

Last Updated: Aug 16, 2025

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.7K
Detection and Isolation of Viable Mouse IL-17-Secreting T Cells
12:38

Detection and Isolation of Viable Mouse IL-17-Secreting T Cells

Published on: December 18, 2008

11.3K
Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

579

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organs.
  • SLE is characterized by immune system dysregulation, including overactive B and T cells.
  • Interleukin-17 (IL-17), a pro-inflammatory cytokine, is implicated in various autoimmune and inflammatory conditions.

Purpose of the Study:

  • To review the critical role of IL-17 in the pathogenesis of SLE.
  • To explore the therapeutic potential of targeting IL-17 in SLE treatment.

Main Methods:

  • Literature search of PubMed database.
  • Keywords included: interleukin-17, systemic lupus erythematosus, treatment targets, T cells, lupus nephritis.

Main Results:

  • Detailed discussion of IL-17 molecular mechanisms, Th17 cell proliferation, and the IL-17/Th17 axis in SLE.
  • Evidence suggests IL-17 is a significant factor in SLE development and progression.
  • IL-17-targeted therapies demonstrate considerable potential for SLE management.

Conclusions:

  • IL-17 is a highly promising therapeutic target for SLE.
  • Further development of IL-17-targeted treatments is warranted for SLE patients.